Polifarma Spa
Polifarma Spa is an Italian pharmaceutical company founded in 1919 that develops and markets prescription drugs and digital therapeutics across cardiovascular, central nervous system, gastroenterology, ophthalmology, and respiratory therapeutic areas, serving specialists and patients in Italy and 27+ countries via a sales-rep network and recent German Hennig acquisition.
- Company typePrivate
- Founded1919
- HeadquartersRome, Italy
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Polifarma Spa does
Polifarma Spa is an Italian pharmaceutical company founded in Rome in 1919, operating as a private SpA within the Final Holding group. The company develops and markets pharmaceutical products across five therapeutic verticals: central nervous system (including vertigo), gastroenterology, ophthalmology, cardiovascular, and infectious/respiratory diseases. Core marketed products include Almarytm (antiarrhythmic, handled via Viatris partnership), Icomb (ramipril-amlodipine combination for hypertension), and the Melatonina Pierpaoli line for sleep wellness. Distribution is conducted through a dedicated network of Pharmaceutical Sales Representatives (Informatori Scientifici del Farmaco) who provide medical-scientific information to specialists (cardiologists, gastroenterologists, ophthalmologists, neurologists) across Italy, supported by an ISO 9001 certified quality management system.
The company differentiates through a 'bio-digital' therapeutic model, coupling drugs with proprietary Digital Medical Devices currently in development: QK-D for hypertension management (co-developed with daVi Digital Medicine), DarSana for telecontrol of visual acuity in age-related macular degeneration, and ISO-D for guiding colonoscopy preparation alongside a macrogol-based bowel cleansing product. The website also offers a Salutepedia patient education platform and a Reserved Area for healthcare professionals.
The business model combines traditional one-time pharmaceutical product sales with subscription/recurring revenue potential from the digital therapeutics pipeline. In February 2025, Polifarma completed the acquisition of 100% of Germany's Hennig Arzneimittel GmbH & Co. KG, a 125+ year-old pharmaceutical company operating a CDMO with capacity exceeding 6 billion units annually and exports to 27+ countries, adding neurology, psychiatry, gastroenterology, and cardiology products plus contract manufacturing revenue. The deal transformed Polifarma into a multi-country European pharmaceutical group and earned the German M&A Award 2025 'Best Family Business Deal'.
Polifarma Spa firmographics
Firmographics- Name
- Polifarma Spa
- Legal name
- Polifarma SpA
- Website
- https://polifarma.it
- Company type
- Private
- Founded year
- 1919
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Polifarma Spa is an Italian pharmaceutical company founded in 1919 that develops and markets prescription drugs and digital therapeutics across cardiovascular, central nervous system, gastroenterology, ophthalmology, and respiratory therapeutic areas, serving specialists and patients in Italy and 27+ countries via a sales-rep network and recent German Hennig acquisition.
- Ownership category
- akta.pro rank
Polifarma Spa industry classification
Industry- Product category
- Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Pharmaceutical Preparations (2834), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
Keywords
Where Polifarma Spa is headquartered
LocationHeadquarters
- HQ city
- Rome
- HQ country
- Italy
- HQ region
- Europe
Offices2 records
Markets served
Polifarma Spa business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure
Revenue model
- Pharmaceutical Products: Traditional pharmaceutical products across therapeutic areas including cardiovascular, gastroenterology, central nervous system, ophthalmology, and infectious diseases. Products include Almarytm (arrhythmia treatment), Icomb (hypertension), and melatonin products.
- Digital Therapeutics (DTx): Bio-digital therapies combining drug therapy with digital applications for chronic disease management including hypertension, ophthalmology, and gastroenterology.
- CDMO Services: Contract Development and Manufacturing Organization services through subsidiary Hennig Arzneimittel.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Polifarma Spa product offering
Product offeringCore offering
Polifarma Spa is an Italian pharmaceutical company founded in 1919 and headquartered in Rome. The company develops, manufactures, and markets branded pharmaceutical products and digital therapeutics across cardiology, gastroenterology, central nervous system, ophthalmology, and infectious diseases. Its portfolio combines traditional drug formulations with proprietary digital medical devices/software-as-a-medical-device offerings.
Product overview
Polifarma Spa is an Italian pharmaceutical company established in 1919, operating as a 'Smart Pharma Company' that develops and markets pharmaceutical products and bio-digital therapies. The company offers a portfolio spanning five therapeutic areas: Central Nervous System, Gastroenterology, Ophthalmology, Cardiovascular, and Infectious Diseases/Respiratory. Product portfolio includes traditional pharmaceuticals (Almarytm for arrhythmias, Icomb for hypertension, Melatonina Pierpaoli for sleep wellness) and Digital Therapeutics (QK-D for hypertension, DarSana for AMD telecontrol, ISO-D for colonoscopy preparation). Following the February 2025 acquisition of Hennig Arzneimittel, the group now includes Polifarma S.p.A., Polifarma Benessere, and Hennig Arzneimittel GmbH & Co. KG.
Differentiator
Problem solved
Functional benefit
Products and services
- Almarytm
Quantifiable outcome
- Awarded German M&A Award 2025 - Best Family Business Deal
- +4 more outcomes
Companies that use Polifarma Spa
Customer profileNamed customers2 records
Segments5 records
Ideal customer profiles2 records
Polifarma Spa technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Polifarma Spa partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- ViatriscorePartnership for Almarytm, a reference molecule for arrhythmia treatment. Polifarma handles medical-scientific information for this product, expanding their cardiovascular portfolio.
- Hennig Arzneimittel GmbH & Co. KGcorePolifarma acquired 100% of German pharmaceutical company Hennig Arzneimittel in February 2025. Hennig specializes in vertigo treatment, neurology, psychiatry, gastroenterology, and cardiology, and operates as a CDMO. The acquisition strengthens Polifarma's international presence and adds manufacturing capabilities with over 6 billion units annual capacity.
- Laife ReplycoreCollaboration for development of a new digital therapy for hypertension, combining pharmaceutical and digital solutions.
- daVi Digital Medicine S.r.l.coreCo-development of QK-D Digital Medical Device for hypertension treatment. daVi provides digital medicine expertise for the bio-digital therapeutic.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Polifarma Spa competitors and assessment
Company assessmentDirect peers
- Chiesi Farmaceutici: Private Italian specialty pharmaceutical company with a comparable multi-therapeutic-area model (respiratory, neonatology, rare disease) and a parallel international expansion strategy. Polifarma overlaps with Chiesi on the pattern of an Italian family/private pharma building global specialty franchises.
- Dompé: Italian biopharmaceutical company with a portfolio spanning ophthalmology, primary care and rare diseases — overlapping Polifarma's ophthalmology (AMD/DarSana) and primary care franchises. Comparable as a privately-controlled Italian pharma investing in specialty innovation.
- Italfarmaco: Private Italian pharma with specialty and rare disease franchises, including cardiovascular and CNS overlap. Comparable to Polifarma as a similarly-sized privately-held Italian specialty pharma building international reach.
- Molteni Farmaceutici: Italian privately-held specialty pharma focused on pain/addiction/psychiatry with strong manufacturing capabilities. Comparable to Polifarma on size, ownership structure and the combination of branded pharma + domestic manufacturing expertise.
- Zambon: Italian family-owned pharma group operating across CNS, respiratory and pain with international manufacturing/CDMO elements. Highly comparable to Polifarma as another privately-controlled Italian mid-cap pharma pursuing therapeutic diversification and global expansion.
- Recordati: Public Italian specialty pharma with strong cardiovascular/urology/endocrinology franchises — directly comparable to Polifarma's Almarytm/Icomb cardiovascular focus — and a track record of cross-border European bolt-on M&A analogous to Polifarma's Hennig deal.
- Menarini Group: Italy's largest privately-held pharma group with a similarly broad therapeutic footprint spanning cardiology, oncology, gastroenterology, and anti-infectives. Comparable to Polifarma as a privately controlled Italian pharma leveraging a wide portfolio plus international expansion through acquisitions.
- Angelini Pharma: Italian family-owned pharma (part of Angelini Industries) with CNS, pain and consumer health portfolios. Directly comparable to Polifarma on the family/private ownership model and CNS therapeutic overlap (Polifarma's vertigo/SNC area).
Emerging players
- Voluntis: Digital therapeutics company developing software-based treatments for chronic conditions including oncology and diabetes. Comparable to Polifarma's QK-D, DarSana and ISO-D as an emerging DTx player pursuing similar pharma-partnered commercialization models.
Broad incumbents
- Stada Arzneimittel: German-headquartered specialty and generics pharma with significant CDMO operations and pan-European distribution — directly comparable to the Hennig Arzneimittel business Polifarma just acquired. Larger and broader than Polifarma but the most direct benchmark for the German CDMO/international leg of the group's strategy.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Polifarma Spa social profiles
Digital presencePolifarma Spa compliance and trust
Trust signalCompliance1 record
Polifarma Spa financial estimates
Financial estimateRevenue estimate
Valuation estimate
Polifarma Spa leadership team
Management profileNumber of profiles
Profiles1 record
Polifarma Spa subsidiaries and ownership
Company hierarchySubsidiaries3 records
Polifarma Spa funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Polifarma Spa M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Polifarma Spa
What does Polifarma Spa do?
Polifarma Spa is an Italian pharmaceutical company founded in 1919 and headquartered in Rome. The company develops, manufactures, and markets branded pharmaceutical products and digital therapeutics across cardiology, gastroenterology, central nervous system, ophthalmology, and infectious diseases. Its portfolio combines traditional drug formulations with proprietary digital medical devices/software-as-a-medical-device offerings.
Is Polifarma Spa a public or private company?
Polifarma Spa is a private company. It is classified as family owned and is currently operating.
When was Polifarma Spa founded?
Polifarma Spa was founded in 1919. It employs 101 to 250 people.
Where is Polifarma Spa based?
Polifarma Spa is headquartered in Rome, Italy, in the Europe region.
How does Polifarma Spa make money?
Three revenue lines are on record. Pharmaceutical Products are the primary driver. The others are digital Therapeutics (DTx) and CDMO Services.
Who are Polifarma Spa's main competitors?
Direct peers on record are Chiesi Farmaceutici, Dompé, Italfarmaco, Molteni Farmaceutici, Zambon, Recordati, Menarini Group and Angelini Pharma. Voluntis is listed as an emerging player. Stada Arzneimittel is listed as a broad incumbent.
Does Polifarma Spa have an API?
No public API is recorded for Polifarma Spa.
What industry is Polifarma Spa in?
Polifarma Spa's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 3254 and its SIC code is 2834.